Payment overview · 2025
General Payments
$504.23
24 reported records · 7 companies
Healthcare provider profile · identity verified
Sukh Dev Singh Khalsa, P.M.H.N.P.
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Psychiatric/Mental Health · RIVERSIDE, CA · NPI 1881978682
Verified facts
What the public records show
CMS Open Payments records show Sukh Dev Singh Khalsa, P.M.H.N.P. received $504.23 in general payments during 2025 across 24 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aplenzin, Lybalvi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lybalvi by this doctor in 2024.
Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APLENZIN as an associated drug or biological on 9096 records involving 3309 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Aplenzin by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $167.12 | 33.1% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $155.79 | 30.9% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $86.31 | 17.1% | 4 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.64 | 6.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.38 | 4.8% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $18.49 | 3.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.50 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $504.23 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $167.12 | 5 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $155.79 | 10 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $155.79 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.31 | 4 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $34.64 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| APLENZIN aplenzin |
2025 | Aplenzin | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | APLENZIN open payments reported associated product |
CMS Open Payments — General Payments 9096 supporting records · 3309 recipient NPIs · example record 1239973605 |
Aplenzin · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 254 | 37 |
| Lorazepam | Lorazepam | 219 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 34 |
| Clonazepam | Clonazepam | 195 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 181 | 29 |
| Trazodone Hcl | Trazodone Hcl | 174 | 42 |
| Sertraline Hcl | Sertraline Hcl | 142 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | 23 |
| Aripiprazole | Aripiprazole | 113 | 21 |
| Lamotrigine | Lamotrigine | 112 | 24 |
| Mirtazapine | Mirtazapine | 108 | 25 |
| Doxepin Hcl | Doxepin Hcl | 104 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 87 | 18 |
| Bupropion Xl | Bupropion Hcl | 82 | 18 |
| Temazepam | Temazepam | 80 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 73 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 70 | 15 |
| Olanzapine | Olanzapine | 70 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 12 |
| Lurasidone Hcl | Lurasidone Hcl | 61 | suppressed |
| Gabapentin | Gabapentin | 60 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 52 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 52 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Diazepam | Diazepam | 49 | suppressed |
| Modafinil | Modafinil | 48 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 36 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 32 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 31 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 29 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 25 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Aplenzin | Bupropion Hbr | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 23 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Omeprazole | Omeprazole | 17 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Dyanavel Xr | Amphetamine | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $504.23 · 24 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABILIFY ASIMTUFII, ABILIFY MAINTENA, APLENZIN, ARISTADA, CAPLYTA, COBENFY, LYBALVI, VRAYLAR, Xelstrym | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aplenzin play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error